PT2379600E - Anticorpos contra inibidor da via de fator tecidual - Google Patents
Anticorpos contra inibidor da via de fator tecidual Download PDFInfo
- Publication number
- PT2379600E PT2379600E PT97935431T PT09793543T PT2379600E PT 2379600 E PT2379600 E PT 2379600E PT 97935431 T PT97935431 T PT 97935431T PT 09793543 T PT09793543 T PT 09793543T PT 2379600 E PT2379600 E PT 2379600E
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies against
- tissue factor
- pathway inhibitor
- against tissue
- factor pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08172520 | 2008-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2379600E true PT2379600E (pt) | 2014-04-29 |
Family
ID=40639722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97935431T PT2379600E (pt) | 2008-12-22 | 2009-12-18 | Anticorpos contra inibidor da via de fator tecidual |
Country Status (19)
Country | Link |
---|---|
US (5) | US8361469B2 (pt) |
EP (3) | EP2746294A3 (pt) |
JP (2) | JP5714505B2 (pt) |
KR (2) | KR101600308B1 (pt) |
CN (1) | CN102325795B (pt) |
AU (1) | AU2009331570C1 (pt) |
BR (1) | BRPI0924058B1 (pt) |
CA (1) | CA2745317C (pt) |
DK (1) | DK2379600T4 (pt) |
ES (1) | ES2458665T5 (pt) |
FR (1) | FR24C1008I1 (pt) |
IL (1) | IL213356A (pt) |
MX (1) | MX2011006501A (pt) |
PL (1) | PL2379600T5 (pt) |
PT (1) | PT2379600E (pt) |
RU (1) | RU2562114C2 (pt) |
TW (1) | TWI476003B (pt) |
WO (1) | WO2010072691A1 (pt) |
ZA (1) | ZA201104599B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010000721A1 (en) | 2008-06-30 | 2010-01-07 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
MX2011006501A (es) | 2008-12-22 | 2011-07-12 | Novo Nordisk As | Anticuerpos contra inhibidor de la via de factor de tejido. |
US8454956B2 (en) | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
MX2012009755A (es) * | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
SG10201502587SA (en) | 2010-03-01 | 2015-06-29 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US20130136733A1 (en) * | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
US9228022B2 (en) | 2010-06-30 | 2016-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
CN103080135B (zh) * | 2010-06-30 | 2017-06-13 | 诺沃—诺迪斯克有限公司 | 能够特异性结合组织因子途径抑制剂的抗体 |
AU2012236296A1 (en) * | 2011-04-01 | 2013-10-24 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
US9221904B2 (en) | 2012-07-19 | 2015-12-29 | National Cheng Kung University | Treatment of osteoarthritis using IL-20 antagonists |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
PL2970497T3 (pl) | 2013-03-15 | 2018-05-30 | Bayer Healthcare Llc | Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki |
EP2970498A4 (en) * | 2013-03-15 | 2016-11-23 | Bayer Healthcare Llc | PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR |
CN105209497B (zh) * | 2013-03-15 | 2021-09-07 | 诺和诺德股份有限公司 | 能够特异性结合组织因子途径抑制物上的两个表位的抗体 |
US10457743B2 (en) | 2013-07-19 | 2019-10-29 | Novo Nordisk A/S | Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
CN106659909B (zh) | 2013-08-21 | 2022-01-11 | 德克萨斯州大学***董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
RS59480B1 (sr) * | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena |
EP3137502B1 (en) * | 2014-04-27 | 2020-07-29 | FameWave Ltd. | Humanized antibodies against ceacam1 |
US11279771B2 (en) | 2014-09-17 | 2022-03-22 | Novo Nordisk A/S | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
CN112225812A (zh) * | 2015-02-25 | 2021-01-15 | 财团法人牧岩生命科学研究所 | 结合tfpi的新型抗体以及包含所述抗体的组合物 |
PE20240142A1 (es) * | 2015-08-19 | 2024-02-01 | Pfizer | Anticuerpos inhibidores via del factor tisular y usos de los mismos |
AU2017224122B2 (en) | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
AR110755A1 (es) * | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
JP7094722B2 (ja) * | 2018-02-28 | 2022-07-04 | キヤノン株式会社 | 画像読取装置及び画像形成装置 |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
EP3863664A1 (en) * | 2018-10-11 | 2021-08-18 | Pfizer Inc. | Dosage regimen for tfpi antagonists |
CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
WO2021094917A1 (en) * | 2019-11-13 | 2021-05-20 | Pfizer Inc. | Stable aqueous anti-tfpi antibody formulation |
CN117487017A (zh) * | 2020-07-02 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 |
US20230357432A1 (en) | 2020-09-24 | 2023-11-09 | Novo Nordisk Health A/S | Pharmaceutical formulation of concizumab and method of production thereof |
WO2023143559A1 (en) * | 2022-01-30 | 2023-08-03 | Westlake University | Tfpi binding polypeptides and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966852A (en) * | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
EP0539975A1 (en) † | 1991-10-31 | 1993-05-05 | Teijin Limited | Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor |
JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
JPH06153981A (ja) | 1992-11-30 | 1994-06-03 | Teijin Ltd | Laciの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体 |
US5455338A (en) * | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
JPH0875736A (ja) | 1994-09-06 | 1996-03-22 | Chemo Sero Therapeut Res Inst | ヒト組織因子凝固系インヒビターの定量法 |
US5902582A (en) * | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
JP3681206B2 (ja) | 1995-12-26 | 2005-08-10 | 株式会社三菱化学ヤトロン | 抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用 |
AU7266898A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−5γ2結合性ペプチド、その関連組成物およびその使用 |
US7585842B2 (en) | 2004-04-16 | 2009-09-08 | The Reagents Of The University Of California | Human kunitz-type inhibitor with enhanced antifibrinolytic activity |
US7015746B1 (en) * | 2004-05-06 | 2006-03-21 | National Semiconductor Corporation | Bootstrapped bias mixer with soft start POR |
EP1869082B1 (en) † | 2005-03-04 | 2011-04-13 | The Board Of Trustees Of The University Of Illinois | Coagulation and fibrinolytic cascades modulator |
UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
SI2379096T1 (sl) * | 2008-12-19 | 2020-03-31 | Baxalta GmbH | Zaviralci TFPI in postopki uporabe |
JP5791512B2 (ja) * | 2008-12-22 | 2015-10-07 | ノヴォ ノルディスク アー/エス | 組織因子経路阻害因子(tfpi)に対する抗体 |
MX2011006501A (es) * | 2008-12-22 | 2011-07-12 | Novo Nordisk As | Anticuerpos contra inhibidor de la via de factor de tejido. |
US8965454B2 (en) | 2009-03-04 | 2015-02-24 | Andrew Llc | Amplifier system for cell sites and other suitable applications |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
CA2770762A1 (en) | 2009-08-18 | 2011-02-24 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
SG10201502587SA (en) * | 2010-03-01 | 2015-06-29 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US8598008B2 (en) † | 2010-10-20 | 2013-12-03 | Texas Instruments Incorporated | Stacked ESD clamp with reduced variation in clamp voltage |
AU2012214148A1 (en) † | 2011-02-11 | 2013-08-29 | Baxter Healthcare S.A. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
AU2012236296A1 (en) † | 2011-04-01 | 2013-10-24 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
US20130267584A1 (en) † | 2012-03-22 | 2013-10-10 | Baxter Healthcare S.A. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
CN105209497B (zh) | 2013-03-15 | 2021-09-07 | 诺和诺德股份有限公司 | 能够特异性结合组织因子途径抑制物上的两个表位的抗体 |
CN112225812A (zh) † | 2015-02-25 | 2021-01-15 | 财团法人牧岩生命科学研究所 | 结合tfpi的新型抗体以及包含所述抗体的组合物 |
PE20240142A1 (es) † | 2015-08-19 | 2024-02-01 | Pfizer | Anticuerpos inhibidores via del factor tisular y usos de los mismos |
-
2009
- 2009-12-18 MX MX2011006501A patent/MX2011006501A/es active IP Right Grant
- 2009-12-18 KR KR1020117016958A patent/KR101600308B1/ko active IP Right Review Request
- 2009-12-18 EP EP14151704.5A patent/EP2746294A3/en not_active Withdrawn
- 2009-12-18 RU RU2011129068/10A patent/RU2562114C2/ru active
- 2009-12-18 ES ES09793543T patent/ES2458665T5/es active Active
- 2009-12-18 BR BRPI0924058-6A patent/BRPI0924058B1/pt active IP Right Grant
- 2009-12-18 DK DK09793543.1T patent/DK2379600T4/da active
- 2009-12-18 CA CA2745317A patent/CA2745317C/en active Active
- 2009-12-18 CN CN200980157157.2A patent/CN102325795B/zh active Active
- 2009-12-18 AU AU2009331570A patent/AU2009331570C1/en active Active
- 2009-12-18 EP EP17176891.4A patent/EP3260466A1/en not_active Withdrawn
- 2009-12-18 PL PL09793543T patent/PL2379600T5/pl unknown
- 2009-12-18 KR KR1020167005204A patent/KR101745394B1/ko active IP Right Grant
- 2009-12-18 JP JP2011541494A patent/JP5714505B2/ja active Active
- 2009-12-18 EP EP09793543.1A patent/EP2379600B2/en active Active
- 2009-12-18 WO PCT/EP2009/067598 patent/WO2010072691A1/en active Application Filing
- 2009-12-18 US US13/140,296 patent/US8361469B2/en active Active
- 2009-12-18 PT PT97935431T patent/PT2379600E/pt unknown
- 2009-12-22 TW TW098144133A patent/TWI476003B/zh active
-
2011
- 2011-06-05 IL IL213356A patent/IL213356A/en active IP Right Grant
- 2011-06-22 ZA ZA2011/04599A patent/ZA201104599B/en unknown
-
2012
- 2012-12-20 US US13/721,755 patent/US9574011B2/en active Active
- 2012-12-20 US US13/721,802 patent/US8652471B2/en active Active
-
2015
- 2015-03-11 JP JP2015048157A patent/JP6114326B2/ja active Active
-
2017
- 2017-01-06 US US15/400,366 patent/US20170114147A1/en not_active Abandoned
-
2019
- 2019-03-25 US US16/363,327 patent/US20190211112A1/en not_active Abandoned
-
2024
- 2024-02-26 FR FR24C1008C patent/FR24C1008I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282658A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (TFPI) | |
ZA201104599B (en) | Antibodies against tissue factor pathway inhibitor | |
HK1176601A1 (zh) | 抑制劑 | |
EP2272817A4 (en) | INHIBITOR OF PAI-1 | |
EP2207803A4 (en) | CD9-SPECIFIC HUMAN ANTIBODIES | |
ZA201100898B (en) | Novel inhibitors | |
EP2344533A4 (en) | SPECIFIC HUMAN ANTIBODY OF TMPRSS4 | |
ZA201102837B (en) | Phosphodiestarase inhibitors | |
EP2222662A4 (en) | INHIBITORS OF KYNURENINE AMINO TRANSFERASE | |
EP2177529A4 (en) | NEW DE-SECRETASE INHIBITOR | |
GB0820117D0 (en) | Tourniquet | |
GB0714941D0 (en) | Inhibitors | |
HRP20190159T1 (hr) | Antitijela humanog anti-alfa-sinukleina | |
GB201019387D0 (en) | Inhibitors | |
GB0809820D0 (en) | Modified tissues | |
GB0713152D0 (en) | Phosphodlesterase inhibitors | |
GB0816125D0 (en) | Novel inhibitors | |
GB0720364D0 (en) | Inhibitor | |
GB0804978D0 (en) | Reflection | |
GB0707497D0 (en) | Novel inhibitors | |
GB0707495D0 (en) | Novel inhibitors | |
GB0707493D0 (en) | Novel inhibitors | |
GB0707488D0 (en) | Novel inhibitors | |
GB0704589D0 (en) | Novel inhibitors | |
GB0707498D0 (en) | Novel inhibitors |